

# Reference Data

## 3rd Quarter - Fiscal Year 2009

(April 1, 2009 to December 31, 2009)

### Consolidated Earnings

- Consolidated Financial Data P 1
- Consolidated Balance Sheets P 2
- Consolidated P/L Statement P 3
- Consolidated Sales Breakdown by Category P 4
- Consolidated Operating Income by Category P 4
- Consolidated Sales -
  - Leading Brands of Self-Medication Operations P 5
- Consolidated Sales -
  - Leading Products of Prescription Pharmaceutical Operations P 6
- Major Subsidiaries : Trend of Sales and Earnings P 6
- Capital Expenditure P 7
- Depreciation Costs P 7
- R&D Expenses P 7
- Subsidiaries and Affiliates P 8
- <Reference> Sales Data for Each Quarter P 9

### New Drug Development / New Products

- Prescription Pharmaceutical operations:
  - New Drug Development P10
- Launch of New Products P12

## Consolidated Financial Data

(Millions of yen)

	March 2009(FY2008)				March 2010 (FY2009)				
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year E new	Full year E previous
Net Sales	61,853	126,314	199,797	256,213	63,563	129,755	202,930	259,000	262,000
(YOY%)	(+8.7%)	(+4.6%)	(+3.3%)	(+2.6%)	(+2.8%)	(+2.7%)	(+1.6%)	(+1.1%)	(+2.3%)
Self-Medication operations	38,649	82,511	127,392	161,141	38,563	81,636	124,665	158,900	161,900
Prescription Pharmaceutical operations	23,203	43,803	72,405	95,072	24,999	48,118	78,265	100,100	100,100
Gross profit	42,092	84,992	133,291	169,462	41,465	84,497	131,748	168,000	170,200
Selling, general and administrative expenses	30,447	65,509	100,811	131,526	35,209	66,298	102,502	134,500	135,700
Research and development expenses	5,758	15,038	21,437	27,523	9,209	14,440	22,630	28,300	28,400
(% Sales)	(9.3%)	(11.9%)	(10.7%)	(10.7%)	(14.5%)	(11.1%)	(11.2%)	(10.9%)	(10.8%)
Advertising expenses	3,507	7,205	13,180	16,531	4,472	8,434	13,886	17,000	17,300
Sales promotion expenses	5,163	10,906	17,656	23,372	5,805	11,875	18,338	24,500	25,400
Personnel expenses	8,382	16,640	24,902	32,947	8,508	16,844	25,314	33,600	33,800
Operating income	11,644	19,483	32,479	37,935	6,256	18,199	29,245	33,500	34,500
(YOY%)	(+42.5%)	(+1.9%)	(-1.2%)	(+2.7%)	(-46.3%)	(-6.6%)	(-10.0%)	(-11.7%)	(-9.1%)
Ordinary income	12,360	20,757	34,149	39,902	7,074	18,855	30,649	35,500	36,000
(YOY%)	(+26.5%)	(-7.5%)	(-8.6%)	(-4.8%)	(-42.8%)	(-9.2%)	(-10.2%)	(-11.0%)	(-9.8%)
Net income	7,693	-1,053	4,695	8,815	3,580	10,364	15,774	18,500	19,500
(YOY%)	(+27.9%)	( - )	(-79.7%)	(-64.7%)	(-53.5%)	( - )	(+236.0%)	(+109.9%)	(+121.2%)
EPS (yen)	25.87	-3.56	15.94	30.01	12.48	36.14	55.00	64.51	67.99
BPS (yen)	1,830.90	1,778.72	1,754.96	1,745.96	1,769.73	1,790.16	1,790.15	1,801.40	1,808.63
Dividend per share(yen)	-	12.00	-	27.00	-	12.00	-	27.00	27.00
Payout Ratio	-	-	-	90.0%	-	-	-	41.9%	39.7%
Capital expenditure	367	1,859	3,789	5,814	1,185	3,967	19,452	21,700	8,600
Depreciation and amortization	2,625	5,313	8,096	11,014	2,557	5,223	8,350	11,600	11,600
Total assets	625,663	600,679	600,604	591,568	593,411	600,565	602,631	604,000	606,000
Shareholders' equity	552,953	528,605	522,007	514,511	517,203	523,341	523,626	527,000	529,000
Return on equity(%) *	-	-	-	1.7%	-	-	-	3.6%	3.8%
Return on assets(%) *	-	-	-	1.4%	-	-	-	3.1%	3.3%
Equity ratio(%)	87.0%	86.5%	85.4%	85.4%	85.5%	85.5%	85.2%	85.5%	85.6%
Overseas sales	2,776	4,913	6,717	8,184	1,637	3,429	5,134	-	-
(% Sales)	4.5%	3.9%	3.4%	3.2%	2.6%	2.6%	2.5%	-	-
Number of employees	5,504	5,491	5,456	5,409	5,524	5,529	5,625	-	-

E = Estimates

Figures for each quarter are accumulated totals from the beginning of the fiscal year.

\* Average of the beginning and year-end balance of shareholders' equity / total assets

## Consolidated Balance Sheets

(Millions of yen)

	End of FY2008		End of 3Q 2009		Change	
	(March 31, 09)	% total	(Dec. 31, 09)	% total		
<b>(Assets)</b>						
<b>I Current assets:</b>	215,872	36.5%	205,899	34.2%	-9,973	
Cash and deposits	112,989		86,426		-26,563	
Notes and accounts receivable-trade	61,968		84,505		+22,537	Due to last day of third quarter being a public holiday, etc.
Marketable securities	2,918		2,589		-329	Transferred from investment securities: +2,500, Bond redemption: -2,910
Inventories	22,146		22,012		-133	Merchandise and finished goods: -27, work in progress: +37, raw materials and supplies: -143
Deferred tax assets	7,450		6,069		-1,380	Reduced due to one-time difference of allowance for bonuses, etc.
Others	8,398		4,295		-4,103	Money trust for repurchase of treasury shares: -4,713
<b>II Fixed assets:</b>	375,696	63.5%	396,731	65.8%	+21,035	
<b>(1) Tangible fixed assets:</b>	92,961	(15.7%)	91,576	(15.2%)	-1,384	
Buildings and structures	48,681		47,579		-1,102	Buildings: -982, structures: -119
Machinery and equipment	9,211		8,990		-221	Machinery: -247, vehicles: +25
Land	29,652		30,795		+1,143	Acquisition of business-use land
Others	5,415		4,211		-1,203	
<b>(2) Intangible fixed assets:</b>	10,108	(1.7%)	35,003	(5.8%)	+24,894	
Goodwill	2,484		14,399		+11,914	Goodwill for PT. Taisho Indonesia: +12,013
Sales rights	-		11,456		+11,456	Acquisition of Bristol-Myers Squibb Company sales rights
Trademarks	2,443		4,435		+1,991	Acquisition of Bristol-Myers Squibb Company trademark rights: +2,556 VICKS trademark amortization: -563
Software	4,978		4,313		-664	
Others	202		398		+195	
<b>(3) Investments and other assets:</b>	272,626	(46.1%)	270,151	(44.8%)	-2,474	
Investments in securities	205,410		208,258		+2,848	Bond acquisition: +44,079, Bond redemption: -46,000, Increase in evaluation gain: +7,890, Transferred to marketable securities -2,500
Affiliates' stock	46,706		43,601		-3,104	
Deferred tax assets	14,121		12,513		-1,607	Decrease due to increase in evaluation gain of investments in securities
Others	6,388		5,777		-610	
<b>Total assets</b>	<b>591,568</b>	<b>100.0%</b>	<b>602,631</b>	<b>100.0%</b>	<b>+11,062</b>	

<b>(Liabilities)</b>						
<b>I Current liabilities:</b>	54,130	9.1%	56,186	9.3%	+2,056	
Notes and accounts payable-trade	20,149		26,303		+6,153	
Accounts payable	11,265		11,985		+719	
Accrued corporate tax	9,193		4,818		-4,374	
Allowance for bonuses	4,326		1,561		-2,765	
Others	9,194		11,517		+2,323	
<b>II Long-term liabilities:</b>	22,927	3.9%	22,819	3.8%	-108	
Reserves for retirement benefits	15,937		16,639		+702	
Deferred taxes liabilities	424		467		+43	
Others	6,565		5,711		-854	
<b>Total liabilities</b>	<b>77,057</b>	<b>13.0%</b>	<b>79,005</b>	<b>13.1%</b>	<b>+1,947</b>	
<b>(Net assets)</b>						
<b>I Shareholders' equity</b>	516,948	87.4%	520,121	86.3%	+3,172	
Common Stock	29,804	5.0%	29,804	4.9%	-	
Additional paid-in capital	14,935	2.5%	14,935	2.5%	-	
Retained earnings	535,393	90.5%	503,015	83.5%	-32,377	Net income: +10,364, Payment of dividend: -4,343 Cancellation of treasury stock -40,365
Treasury stock	-63,183	-10.6%	-27,633	-4.6%	+35,550	Acquisition of treasury stock -4,772, Cancellation +40,365
<b>II Valuation, translation, adjustments and others</b>	-11,782	-2.0%	-6,740	-1.1%	+5,041	
Unrealized gain on securities	-3,752	-0.6%	1,045	0.2%	+4,797	Increase in evaluation gain of investments in securities
Others	-8,030	-1.4%	-7,786	-1.3%	+243	
<b>III Minority interest</b>	9,344	1.6%	10,245	1.7%	+900	
<b>Total net assets</b>	<b>514,511</b>	<b>87.0%</b>	<b>523,626</b>	<b>86.9%</b>	<b>+9,114</b>	
<b>Total liabilities and net assets</b>	<b>591,568</b>	<b>100.0%</b>	<b>602,631</b>	<b>100.0%</b>	<b>+11,062</b>	

## Consolidated P/L Statement

(Millions of yen)

	FY2008 3Q (April-Dec.)		FY2009 3Q (April-Dec.)		YOY Change	Explanatory comments
		% Sales		% Sales		
Net sales	199,797	100.0%	202,930	100.0%	+3,132	
Cost of sales	66,480	33.3%	71,059	35.0%	+4,578	
Gross profit on sales	133,316	66.7%	131,871	65.0%	-1,445	
Provision for sales returns	25		123		+97	
Gross profit	133,291	66.7%	131,748	64.9%	-1,543	
Selling, general and administrative expenses	100,811	50.4%	102,502	50.5%	+1,690	
Research and development expenses	21,437		22,630		+1,192	Increase due to in-licensing-related payments
Advertising expenses	13,180		13,886		+705	Increase for advertising costs for new products
Sales promotion expenses	17,656		18,338		+682	Increase for sales promotion costs for new products Increase due to response to revision of OTC drugs sales system
Personnel expenses	24,902		25,314		+412	Increase for retirement benefit expenses
Others	23,635		22,332		-1,302	Decrease for amortization of goodwill, etc.
Operating income	32,479	16.3%	29,245	14.4%	-3,233	
Non-operating income	5,074	2.5%	5,142	2.5%	+67	
Non-operating expenses	3,404	1.7%	3,737	1.8%	+333	
Ordinary income	34,149	17.1%	30,649	15.1%	-3,499	
Extraordinary gains	5,417	2.7%	14	0.0%	-5,402	(For same period of previous year) Gain of 4,382 on sale of affiliates' stock Gain of 891 on prior-period adjustment
Extraordinary losses	18,527	9.3%	882	0.4%	-17,645	(For period under review) Loss of 510 due to impairment of idle equipment and facility (For same period of previous year) Losses of 12,852 on lump sum amortization of goodwill, of 2,275 on changes in equity, and of 3,332 on loss on devaluation of investment securities
Income before income taxes and minority interests	21,039	10.5%	29,782	14.7%	+8,743	
Income taxes	15,368	7.7%	12,810	6.3%	-2,557	
Minority interest gain (loss) of consolidated subsidiaries	975	0.5%	1,197	0.6%	+221	
Net income	4,695	2.3%	15,774	7.8%	+11,079	

Figures for each quarter are accumulated totals from the beginning of the fiscal year.

## Consolidated Sales Breakdown by Category

(Millions of yen)

	March 2009(FY2008)				March 2010 (FY2009)				
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year E new	Full year E previous
Self-Medication operations (YOY%)	38,649 (+11.5%)	82,511 (+9.5%)	127,392 (+7.5%)	161,141 (+5.5%)	38,563 (-0.2%)	81,636 (-1.1%)	124,665 (-2.1%)	158,900 (-1.4%)	161,900 (+0.5%)
OTC products, etc.	35,616	75,990	117,316	148,229	35,184	74,417	113,782	144,800	148,100
Foods for Specified Health Use, etc.	2,366	5,004	7,727	9,921	2,415	5,243	7,943	10,100	9,800
Others	667	1,517	2,349	2,991	964	1,976	2,940	4,000	4,000
Prescription Pharmaceutical operations (YOY%)	23,203 (+4.4%)	43,803 (-3.5%)	72,405 (-3.4%)	95,072 (-2.0%)	24,999 (+7.7%)	48,118 (+9.9%)	78,265 (+8.1%)	100,100 (+5.3%)	100,100 (+5.3%)
Ethical drugs	19,943	38,337	64,646	84,712	22,851	43,804	70,938	90,200	90,200
Others	2,083	4,180	6,400	8,748	2,012	4,133	7,094	9,400	9,400
Royalty income	1,177	1,286	1,359	1,612	136	181	233	500	500
Total	61,853	126,314	199,797	256,213	63,563	129,755	202,930	259,000	262,000

E=Estimates

Figures for each quarter are accumulated totals from the beginning of the fiscal year.

## Consolidated Operating Income by Category

(Millions of yen)

	March 2009(FY2008)				March 2010 (FY2009)				
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year E new	Full year E previous
Self-Medication operations (YOY%)	8,863 (+70.5%)	18,663 (+33.0%)	25,631 (+10.6%)	29,227 (+11.7%)	6,516 (-26.5%)	16,098 (-13.7%)	24,836 (-3.1%)	28,400 (-2.8%)	29,700 (+1.6%)
Prescription Pharmaceutical operations (YOY%)	2,781 (-6.6%)	820 (-83.9%)	6,847 (-29.4%)	8,707 (-19.2%)	-259 (-)	2,100 (+156.1%)	4,409 (-35.6%)	5,100 (-41.4%)	4,800 (-44.9%)
Total	11,644	19,483	32,479	37,935	6,256	18,199	29,245	33,500	34,500

E=Estimates

Figures for each quarter are accumulated totals from the beginning of the fiscal year.

## Consolidated Sales - Leading Brands of Self-Medication Operations

(Billions of yen)

	March 2009(FY2008)				March 2010 (FY2009)					
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	3Q (4-12)	YOY	Full year E new	Full year E previous
Lipovitan series	19.7	42.4	61.5	74.8	18.5	39.9	58.0	-5.7%	70.7	71.9
Lipovitan D	14.4	30.4	43.6	52.8	13.3	28.1	40.7	-6.8%	49.3	49.7
Others	5.4	12.0	17.9	22.0	5.3	11.8	17.3	-3.0%	21.5	22.2
(100mL other Lipovitans)	3.3	7.3	10.8	13.3	3.3	7.3	10.6	-1.8%	13.1	13.5
(50mL other Lipovitans)	2.1	4.7	7.0	8.7	2.0	4.4	6.7	-4.9%	8.4	8.7
Pabron series	4.3	9.4	18.2	25.4	4.7	10.6	18.6	+2.1%	25.5	26.6
RiUP series	2.8	5.8	9.0	11.4	3.3	6.4	9.9	+9.6%	12.7	12.7
Gastrointestinal treatment series	1.0	2.1	3.5	4.4	1.0	2.1	3.4	-2.1%	4.4	4.3
ZENA series	1.0	1.9	3.0	3.9	0.9	1.7	2.7	-11.2%	3.5	3.5
Naron Series	1.0	2.1	3.3	4.4	1.1	2.3	3.4	+3.4%	4.5	4.6
Colac Series	0.9	1.9	3.0	3.9	1.0	1.9	3.0	+1.3%	4.0	4.0
VICKS series	0.4	0.9	2.3	2.9	0.4	1.1	2.4	+7.6%	3.1	3.2
Livita series	0.7	1.3	2.0	2.6	0.7	1.4	2.3	+17.1%	3.1	3.0
Overseas drinks	1.4	3.1	4.7	6.0	1.3	2.8	4.2	-10.2%	5.7	5.4

(Rounded to the nearest hundred-million)

E=Estimates

Figures for each quarter are accumulated totals from the beginning of the fiscal year.

## Energy Drinks: Domestic Sales Breakdown by Channel (parent basis)

(Billions of yen)

	March 2009(FY2008)				March 2010 (FY2009)			
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	3Q (4-12)	YOY
Drug-oriented channels	10.6	22.6	32.8	39.9	10.0	20.7	30.1	-8.1%
Food-oriented channels	10.3	22.4	32.7	40.0	9.8	21.7	31.6	-3.3%
Total	20.9	45.0	65.5	79.9	19.7	42.4	61.8	-5.7%

(Rounded to the nearest hundred-million)

Figures for each quarter are accumulated totals from the beginning of the fiscal year.

## Lipovitan D: Domestic Sales Breakdown by Channel (parent basis)

(Billions of yen)

	March 2009(FY2008)				March 2010 (FY2009)			
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	3Q (4-12)	YOY
Drug-oriented channels	6.7	14.0	19.9	23.7	6.1	12.2	17.6	-11.3%
Food-oriented channels	7.7	16.4	23.8	29.1	7.2	15.9	23.0	-3.1%
Total	14.4	30.4	43.6	52.8	13.3	28.1	40.7	-6.8%

(Rounded to the nearest hundred-million)

Figures for each quarter are accumulated totals from the beginning of the fiscal year.

## Consolidated Sales - Leading Products of Prescription Pharmaceutical Operations

(Billions of yen)

	March 2009(FY2008)				March 2010 (FY2009)				
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	3Q (4-12)	YOY	Full year E
Clarith	5.7	9.8	17.4	24.0	5.4	10.1	18.0	+3.7%	24.4
Palux	2.9	5.6	8.7	11.2	2.8	5.5	8.6	-1.8%	11.0
Zosyn*	0.4	0.9	2.4	4.0	2.5	5.1	8.3	+251.4%	10.2
Geninax	0.1	1.0	3.3	3.7	1.6	2.7	4.8	+43.3%	5.4
PENTCILLIN	1.5	2.9	4.5	5.5	1.2	2.3	3.5	-21.5%	4.4
Lorcam	1.1	2.1	3.1	4.0	1.0	2.0	2.9	-6.5%	3.8
TOMIRON	0.7	1.3	2.3	3.0	0.7	1.2	2.0	-11.6%	2.6
OZEX	0.7	1.3	2.2	3.0	0.6	1.2	1.9	-16.5%	2.6
LUPRAC	0.6	1.1	1.6	2.1	0.5	1.1	1.6	+1.2%	2.1
Mettigine	0.5	1.0	1.5	1.9	0.5	1.0	1.5	-2.0%	1.9

(Rounded to the nearest hundred-million)

\* Figures for March 2009 were including sales of Tazocin

E=Estimates

Figures for each quarter are accumulated totals from the beginning of the fiscal year.

## Major Subsidiaries: Trend of Sales and Earnings

### Sales and Earnings of Taisho Toyama Pharmaceutical

(Billions of yen)

	March 2009(FY2008)				March 2010 (FY2009)					
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	3Q (4-12)	YOY	Full year E new	Full year E previous
Net Sales	19.2	36.9	62.4	81.7	22.0	42.2	68.5	+9.9%	87.0	87.0
Taisho products	14.5	27.9	47.0	61.3	15.7	29.9	49.1	+4.5%	62.8	62.8
Toyama Chemical products	4.7	9.0	15.3	20.5	6.3	12.3	19.4	+26.7%	24.2	24.2
Operating income	0.1	0.5	3.3	3.7	1.5	2.6	4.6	+39.4%	4.0	3.4
Ordinary income	0.1	0.5	3.3	3.7	1.5	2.6	4.6	+39.2%	4.0	3.4
Net income	-0.1	0.1	1.6	1.7	0.8	1.3	2.4	+49.4%	1.9	1.5

(Rounded to the nearest hundred-million)

E=Estimates

Figures for each quarter are accumulated totals from the beginning of the fiscal year.

### Sales and Earnings of Biofermin Pharmaceutical

(Billions of yen)

	March 2009(FY2008)				March 2010 (FY2009)				
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	3Q (4-12)	YOY	Full year E
Net Sales	2.2	4.4	6.6	8.5	2.1	4.4	6.5	-2.0%	8.4
Self-Medication	1.4	2.9	4.3	5.5	1.3	2.8	4.0	-5.2%	5.2
RX Pharmaceutical	0.8	1.5	2.4	3.1	0.8	1.6	2.5	+3.8%	3.2
Operating income	0.5	1.1	1.7	2.1	0.7	1.3	1.8	+5.2%	1.8
Ordinary income	0.6	1.2	1.8	2.2	0.7	1.3	1.8	+4.2%	1.9
Net income	0.3	0.7	1.1	1.4	0.4	0.8	1.1	-0.3%	1.1

(Rounded to the nearest hundred-million)

E=Estimates

Figures for each quarter are accumulated totals from the beginning of the fiscal year.

## Consolidated: Capital Expenditure

(Millions of yen)

	March 2009(FY2008)				March 2010 (FY2009)				
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year E new	Full year E previous
Total capital expenditure	367	1,859	3,789	5,814	1,185	3,967	19,452	21,700	8,600
Taisho Pharmaceutical	245	1,469	2,865	4,687	472	2,886	17,942	20,000	6,900
Omiya Factory	82	472	735	1,404	79	770	813	1,400	2,300
Hanyu Factory	25	111	120	131	0	2	10	100	100
Okayama Factory	1	1	10	58	6	15	35	200	200
Research Center	14	203	469	801	19	190	511	1,000	1,100
Others	122	681	1,531	2,293	367	1,908	16,572	17,300	3,200
Subsidiaries	121	390	924	1,126	713	1,081	1,509	1,700	1,700

E = Estimates

Figures for each quarter are accumulated totals from the beginning of the fiscal year.

< Main capital expenditure >

- Non-consolidated

Acquisition of intangible fixed assets (sales rights, trademark rights)

accompanying purchase of Bristol-Myers Squibb Company's OTC business in Asia: ¥14,371 million

- Subsidiaries

Biofermin: ¥783 million

## Consolidated: Depreciation Costs

(Millions of yen)

	March 2009(FY2008)				March 2010 (FY2009)				
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year E new	Full year E previous
Depreciation and amortization	2,625	5,313	8,096	11,014	2,557	5,223	8,350	11,600	11,600
Cost of sales	1,159	2,329	3,491	4,742	1,050	2,150	3,317	4,700	4,400
SGA expenses	1,465	2,984	4,605	6,272	1,507	3,073	5,033	6,900	7,200

E = Estimates

Figures for each quarter are accumulated totals from the beginning of the fiscal year.

## Consolidated: R&D Expenses

(Millions of yen)

	March 2009(FY2008)				March 2010 (FY2009)				
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year E new	Full year E previous
Total R&D expenses	5,758	15,038	21,437	27,523	9,209	14,440	22,630	28,300	28,400
Self-Medication operations	1,241	3,024	5,753	7,222	1,741	3,032	4,304	5,900	6,000
Prescription Pharmaceutical	4,517	12,014	15,685	20,300	7,467	11,407	18,325	22,400	22,400

E = Estimates

Figures for each quarter are accumulated totals from the beginning of the fiscal year.

## Subsidiaries and Affiliates

(As of December 31, 2009)

Company	Address	Capital	Business	Ownership <sup>*1</sup>
(1) Consolidated subsidiaries				%
Taisho Kosei Service Co.,Ltd.	Tokyo, Japan	.000 Yen 10,000	SMG	100
Taisho Okinawa Co.,Ltd.	Okinawa, Japan	.000 Yen 50,000	SMG	100
Taisho M.T.C. Co.,Ltd.	Tokyo, Japan	.000 Yen 400,000	SMG	60
Taisho Pharmaceutical Logistics Co.,Ltd.	Saitama, Japan	.000 Yen 30,000	SMG	100
Biofermin Pharmaceutical Co., Ltd.	Hyogo, Japan	.000 Yen 1,227,000	SMG PD	56
Taisho Toyama Pharmaceutical Co.,Ltd.	Tokyo, Japan	.000 Yen 2,000,000	PD	70
Medwell Taisho Co.,Ltd.	Saitama, Japan	.000 Yen 200,000	PD	100
Mejiro Real Estate Co.,Ltd.	Tokyo, Japan	.000 Yen 600,000	SMG	100
Shimoda Central Co.,Ltd.	Tokyo, Japan	.000 Yen 300,000	SMG	100
TAISHO ACTIVE HEALTH Co., Ltd.	Tokyo, Japan	.000 Yen 100,000	SMG	55
Taisho Pharmaceutical (Taiwan) Co.,Ltd.	Taiwan	.000 NT\$ 200,000	SMG	100
Taisho Pharmaceutical California Inc.	U.S.A.	.000 US\$ 41,050	SMG	100
Taisho Pharmaceutical (M) SDN. BHD.	Malaysia	.000 M\$ 24,380	SMG	100
Taisho Pharmaceuticals (Philippines), Inc.	Philippines	.000 Peso 18,900	SMG	100
PT. Taisho Indonesia	Indonesia	.000 rupiah 42,920,000	SMG	100
Taisho Foods Deutschland GmbH	Germany	.000 Euro 306	SMG	100
Taisho Co.,Ltd. Shanghai	China	.000 CNY 132,621	SMG	100
Taisho Pharmaceutical Asia (M) SDN. BHD.	Malaysia	.000 M\$ 26,500	SMG	100
Taisho Pharmaceutical (Europe) Ltd.	United Kingdom	.000 £ 20,000	SMG	100
Taisho Vietnam Co.,Ltd.	Vietnam	.000 VND 170,754,300	SMG	100
Taisho Pharmaceutical (H.K.) Ltd.	China	.000 HK\$ 163,000	SMG	100
Osotspa Taisho Co.,Ltd.	Thailand	.000 THB 15,000	SMG	49
Taisho Pharmaceutical R&D Inc.	U.S.A.	.000 US\$ 4,000	PD	100
PT. Taisho Pharmaceutical Indonesia Tbk <sup>*2</sup>	Indonesia	.000 rupiah 10,240,000	SMG	99
Taisho Pharmaceutical Singapore Private Limited <sup>*3</sup>	Singapore	.000 US\$ 1,000	SMG	100
(2) Equity Accounting Method				
Toyama Chemical Co.,Ltd.	Tokyo, Japan	.000 Yen 37,400,593	PD	34
Yomeishu Seizo Co., Ltd.	Tokyo, Japan	.000 Yen 1,650,000	SMG	21
Taisho Hizon Manufacturing Inc.	Philippines	.000 Peso 17,000	SMG	50

SMG=Self-Medication operations PD=Prescription Pharmaceutical operations

\*1 including indirect ownership

\*2 Acquisition of shares from Bristol-Myers Squibb Company of the U.S. on October 30, 2009 (U.S. time).

\*3 Established on October 19, 2009.

The monetary figure in the "Capital" column is the capital after an increase on January 13, 2010.

<Reference> Sales Data for Each Quarter (Three months)

Consolidated Sales - Leading Brands of Self-Medication Operations

(Billions of yen)

	March 2009(FY2008)			March 2010 (FY2009)						
	1Q (4-6)	2Q (7-9)	3Q (10-12)	1Q (4-6)	YOY	2Q (7-9)	YOY	3Q (10-12)	YOY	Full year E new
Lipovitan series	19.7	22.7	19.1	18.5	-6.0%	21.3	-6.0%	18.1	-5.2%	70.7
Lipovitan D	14.4	16.0	13.2	13.3	-7.9%	14.9	-7.4%	12.6	-5.0%	49.3
Others	5.4	6.7	5.9	5.3	-1.0%	6.5	-2.5%	5.6	-5.5%	21.5
(100mL other Lipovitans)	3.3	4.0	3.5	3.3	+1.6%	4.0	-0.5%	3.3	-6.6%	13.1
(50mL other Lipovitans)	2.1	2.6	2.4	2.0	-5.1%	2.5	-5.6%	2.3	-4.0%	8.4
Pabron series	4.3	5.1	8.8	4.7	+8.3%	5.9	+16.8%	8.0	-9.5%	25.5
RiUP series	2.8	3.0	3.2	3.3	+18.7%	3.1	+2.3%	3.5	+8.5%	12.7
Gastrointestinal treatment series	1.0	1.1	1.4	1.0	+2.4%	1.1	-4.5%	1.3	-3.2%	4.4
ZENA series	1.0	0.9	1.1	0.9	-11.2%	0.9	-7.4%	1.0	-14.3%	3.5
Naron Series	1.0	1.1	1.2	1.1	+9.3%	1.2	+3.1%	1.2	-1.3%	4.5
Colac Series	0.9	1.0	1.1	1.0	+5.1%	1.0	+0.2%	1.1	-0.9%	4.0
VICKS series	0.4	0.5	1.4	0.4	+1.4%	0.7	+39.4%	1.4	-2.1%	3.1
Livita series	0.7	0.6	0.7	0.7	-2.8%	0.7	+30.0%	0.9	+27.0%	3.1
Overseas drinks	1.4	1.8	1.6	1.3	-3.6%	1.5	-15.0%	1.4	-10.5%	5.7

(Rounded to the nearest hundred-million)

E = Estimates

Energy Drinks: Domestic Sales Breakdown by Channel (parent basis)

(Billions of yen)

	March 2009(FY2008)			March 2010 (FY2009)					
	1Q (4-6)	2Q (7-9)	3Q (10-12)	1Q (4-6)	YOY	2Q (7-9)	YOY	3Q (10-12)	YOY
Drug-oriented channels	10.6	12.0	10.2	10.0	-6.2%	10.7	-10.6%	9.5	-7.0%
Food-oriented channels	10.3	12.1	10.3	9.8	-5.2%	11.9	-1.2%	9.9	-3.9%
Total	20.9	24.1	20.5	19.7	-5.7%	22.6	-5.9%	19.4	-5.4%

(Rounded to the nearest hundred-million)

Lipovitan D: Domestic Sales Breakdown by Channel (parent basis)

(Billions of yen)

	March 2009(FY2008)			March 2010 (FY2009)					
	1Q (4-6)	2Q (7-9)	3Q (10-12)	1Q (4-6)	YOY	2Q (7-9)	YOY	3Q (10-12)	YOY
Drug-oriented channels	6.7	7.3	5.9	6.1	-9.4%	6.2	-15.2%	5.4	-8.5%
Food-oriented channels	7.7	8.8	7.3	7.2	-6.5%	8.7	-1.0%	7.2	-2.2%
Total	14.4	16.0	13.2	13.3	-7.9%	14.9	-7.4%	12.6	-5.0%

(Rounded to the nearest hundred-million)

Consolidated Sales - Leading Products of Prescription Pharmaceutical Operations

(Billions of yen)

	March 2009(FY2008)			March 2010 (FY2009)						
	1Q (4-6)	2Q (7-9)	3Q (10-12)	1Q (4-6)	YOY	2Q (7-9)	YOY	3Q (10-12)	YOY	Full year E
Clarith	5.7	4.1	7.6	5.4	-4.3%	4.6	+11.7%	8.0	+5.2%	24.4
Palux	2.9	2.7	3.1	2.8	-0.7%	2.7	-1.6%	3.0	-3.0%	11.0
Zosyn*	0.4	0.5	1.5	2.5	+580.2%	2.6	+428.4%	3.2	+111.4%	10.2
Geninax	0.1	0.9	2.3	1.6	-	1.2	+28.7%	2.0	-12.1%	5.4
PENTCILLIN	1.5	1.4	1.6	1.2	-19.9%	1.1	-18.6%	1.2	-25.7%	4.4
Lorcam	1.1	1.0	1.1	1.0	-4.1%	0.9	-7.2%	1.0	-8.2%	3.8
TOMIRON	0.7	0.6	0.9	0.7	-10.7%	0.6	-3.4%	0.8	-17.6%	2.6
OZEX	0.7	0.6	0.9	0.6	-12.9%	0.5	-9.6%	0.7	-23.7%	2.6
LUPRAC	0.6	0.5	0.6	0.5	-1.1%	0.5	+3.4%	0.6	+1.6%	2.1
Metligine	0.5	0.5	0.5	0.5	-5.3%	0.5	+1.6%	0.5	-2.1%	1.9

(Rounded to the nearest hundred-million) \* Figures for March 2009 were including sales of Tazocin

E = Estimates

# Prescription Pharmaceutical operations: New Drug Development

As of January 29, 2010

## (1) Development in Japan

Filed for application

### 1) Clarith tab. 200

- < Application > Eradication by concomitant therapy (\*1) of *H. pylori* in gastric MALT lymphoma, the stomach after endoscopic resection of early stage gastric cancer, and idiopathic thrombocytopenic purpura
- < Description > Macrolide antibiotic
- < Remarks > Additional indication  
Joint application with 9 companies (\*2)  
\*1 Consists of a proton pump inhibitor (lansoprazole, omeprazole, and rabeprazole sodium), amoxicillin hydrate, and clarithromycin  
\*2 Taisho, ABBOTT JAPAN, Astellas, AstraZeneca, Eisai, Kyowa Hakko Kirin, Shionogi, Takeda, Mitsubishi Tanabe

### 2) CT-081

- < Application > Osteoporosis
- < Development > Co-development with Chugai Pharmaceutical
- < Description > Activated vitamin D<sub>3</sub> derivative
  
- < Remarks > Applied by Chugai Pharmaceutical  
Chugai Pharmaceutical development code: ED-71

Phase 2/3

### 1) CT-064 (Injection)

- < Application > Osteoporosis
- < Development > Co-development with Chugai Pharmaceutical
- < Description > Antiresorptive bisphosphonate
- < Remarks > Chugai Pharmaceutical development code: R484

Phase 2

### 1) TT-063

- < Application > Osteoarthritis, scapulohumeral peri-arthritis, myalgia and other conditions
- < Development > Co-development with Tokuhon
- < Description > Anti-inflammatory analgesic patch formulation containing S-flurbiprofen

### 2) NT-702

- < Application > Asthma
- < Development > Co-development with Nissan Chemical
- < Description > Expressed bronchodilatation and inhibition of cellular infiltration

### 3) NT-702

- < Application > Intermittent claudication caused by arteriosclerosis obliterans
- < Development > Co-development with Nissan Chemical
- < Description > Expressed vasodilation as well as platelet aggregate inhibition

# Prescription Pharmaceutical operations: New Drug Development

As of January 29, 2010

## (1) Development in Japan (continued)

Phase 2
---------

### 4) CT-064 (Oral)

- < Application > Osteoporosis
- < Development > Co-development with Chugai Pharmaceutical
- < Description > Antiresorptive bisphosphonate
- < Remarks > Chugai Pharmaceutical development code: R484

### 5) TS-071

- < Application > Type 1 and 2 diabetes
- < Development > In-house
- < Description > Sodium-dependent glucose cotransporter (SGLT) inhibitor

### 6) TS-022

- < Application > Pruritus caused by atopic dermatitis
- < Development > In-house
- < Description > Prostaglandin derivative
- < Remarks > Overseas: Phase 2

### 7) Palux

- < Application > Intermittent claudication caused by spinal canal stenosis
- < Development > In-house
- < Description > Prostaglandin E1 preparation
- < Remarks > Additional indication

## (2) Development in Overseas Countries

Phase 2
---------

### 1) TS-022

- < Application > Pruritus caused by atopic dermatitis
- < Development > In-house
- < Description > Prostaglandin derivative
- < Remarks > In Japan: Phase 2

# Launch of New Products

As of January 29, 2010

Self-Medication operations
----------------------------

## 1) IRIS CL

< Description > Relaunch of tear-like eye drops packaged in a special preservative-free container, a first for an OTC drug

< Launch > February 2009

---

## 2) Meditreat Cream

< Description > The first OTC cream-type treatment for recurrent vaginal candida formulated with miconazole nitrate

< Launch > March 2009

---

## 3) NARON ACE R

< Description > An antipyretic and analgesic formulated with five active ingredients, centered on the two fever and pain inhibitors ibuprofen and ethenzamide

< Launch > March 2009

---

## 4) Stopan

< Description > A switch-OTC analgesic gastrointestinal treatment formulated with the tiquizium bromide, a prescription-based anticholinergic agent

< Launch > April 2009

---

## 5) Diclotect (Tape, Gel and Lotion)

< Description > A switch-OTC topical analgesic and anti-inflammatory drug formulated with the prescription ingredient diclofenac sodium

< Launch > April 2009

---

## 6) Lipovitan Half

< Description > A 100 mL energy drink containing half the calories of *Lipovitan D*

< Launch > May 2009

---

## 7) RiUP X5

< Description > Pharmaceutical hair regrowth treatment for men formulated with 5% of the active hair regrowth ingredient minoxidil (5 times the amount contained in conventional *RiUP* products)

< Launch > June 2009

---

## 8) Flavan-age

< Description > A supplement sold exclusively by mail order that contains a water-soluble and fat-soluble antioxidative constituent

< Launch > June 2009

---

## Launch of New Products

As of January 29, 2010

Self-Medication operations (continued)
----------------------------------------

### 9) Lipovitan Ace

<Description> An energy drink containing 11 ingredients  
< Launch > August 2009

---

### 10) Anserine Powdered Green Tea

<Description> A powdered green tea formulated with anserine, a functional food material currently in the limelight  
< Launch > September 2009

---

### 11) Pabron Mask 365

<Description> A Japanese-made mask manufactured under the same quality controls  
as hospital-use surgical masks  
< Launch > September 2009

---

### 12) Lipovitan Gold Ace

<Description> An energy mini-drink containing 4 herbal ingredients  
< Launch > October 2009

---

### 13) Wakan-no-Katsuryoku

<Description> Health-enhancement supplement sold only through mail order  
< Launch > November 2009

---

### 14) DENTWELL POs-Ca

<Description> Chewing gum containing POs-Ca, an ingredient developed by Ezaki Glico Co., Ltd.; approved as a Foods for Specified Health Use (FOSHU)  
< Launch > November 2009

---

### 15) Naturalcare Granules<GABA> (stick-type packaging)

<Description> Powdered green tea containing GABA; approved as a Foods for Specified Health Use (FOSHU)  
< Launch > November 2009

---

### 16) Benifuuki Powdered Green Tea

<Description> Powdered green tea made from "benifuuki" tea leaves, which contain large amounts of methylated catechins  
< Launch > January 2010

---

## Launch of New Products

As of January 29, 2010

Self-Medication operations (continued)
----------------------------------------

### **17) Dermarin Grande Powder Spray**

< Description > Powder spray-type athlete's foot treatment containing terbinafine hydrochloride  
< Launch > January 2010

---

Prescription Pharmaceutical operations
----------------------------------------

### **1) OZEX fine granules 15% for pediatric**

< Description > Japan's first pediatric new quinolone antibacterial agent with indications  
for pneumonia and otitis media in children  
< Launch > January 2010

---